Walleye Capital LLC Buys Shares of 25,124 Royalty Pharma plc (NASDAQ:RPRX)

Walleye Capital LLC purchased a new position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 25,124 shares of the biopharmaceutical company's stock, valued at approximately $641,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in RPRX. Franklin Resources Inc. lifted its stake in Royalty Pharma by 5.0% during the 3rd quarter. Franklin Resources Inc. now owns 1,460,515 shares of the biopharmaceutical company's stock valued at $40,705,000 after acquiring an additional 70,130 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Royalty Pharma by 4.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company's stock valued at $79,888,000 after purchasing an additional 130,025 shares in the last quarter. Pallas Capital Advisors LLC acquired a new position in shares of Royalty Pharma in the 4th quarter valued at $2,355,000. Jupiter Asset Management Ltd. purchased a new stake in Royalty Pharma in the 4th quarter valued at approximately $4,950,000. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Royalty Pharma by 303.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 539,995 shares of the biopharmaceutical company's stock valued at $13,926,000 after purchasing an additional 406,123 shares during the period. Institutional investors own 54.35% of the company's stock.

Analyst Ratings Changes

Separately, Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $42.50.

Royalty Pharma Trading Up 0.5 %

NASDAQ RPRX traded up $0.17 on Friday, hitting $32.20. 3,442,452 shares of the stock were exchanged, compared to its average volume of 3,253,767. The company's 50-day moving average price is $32.52 and its two-hundred day moving average price is $29.42. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. Royalty Pharma plc has a 52-week low of $24.05 and a 52-week high of $34.20. The company has a market capitalization of $18.56 billion, a price-to-earnings ratio of 22.21, a P/E/G ratio of 2.31 and a beta of 0.50.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Research analysts predict that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 2.73%. The ex-dividend date is Friday, May 16th. Royalty Pharma's payout ratio is presently 60.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.